These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 28526048)

  • 1. Men's and women's response to treatment and perceptions of outcomes in a randomized controlled trial of injectable opioid assisted treatment for severe opioid use disorder.
    Palis H; Marchand K; Guh D; Brissette S; Lock K; MacDonald S; Harrison S; Anis AH; Krausz M; Marsh DC; Schechter MT; Oviedo-Joekes E
    Subst Abuse Treat Prev Policy; 2017 May; 12(1):25. PubMed ID: 28526048
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hydromorphone Compared With Diacetylmorphine for Long-term Opioid Dependence: A Randomized Clinical Trial.
    Oviedo-Joekes E; Guh D; Brissette S; Marchand K; MacDonald S; Lock K; Harrison S; Janmohamed A; Anis AH; Krausz M; Marsh DC; Schechter MT
    JAMA Psychiatry; 2016 May; 73(5):447-55. PubMed ID: 27049826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characteristics and response to treatment among Indigenous people receiving injectable diacetylmorphine or hydromorphone in a randomised controlled trial for the treatment of long-term opioid dependence.
    Oviedo-Joekes E; Palis H; Guh D; Marchand K; Brissette S; Lock K; MacDonald S; Harrison S; Anis AH; Krausz M; Marsh DC; Schechter MT
    Drug Alcohol Rev; 2018 Jan; 37(1):137-146. PubMed ID: 28593748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of hydromorphone for severe opioid use disorder: findings from the SALOME randomized clinical trial.
    Bansback N; Guh D; Oviedo-Joekes E; Brissette S; Harrison S; Janmohamed A; Krausz M; MacDonald S; Marsh DC; Schechter MT; Anis AH
    Addiction; 2018 Jul; 113(7):1264-1273. PubMed ID: 29589873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The SALOME study: recruitment experiences in a clinical trial offering injectable diacetylmorphine and hydromorphone for opioid dependency.
    Oviedo-Joekes E; Marchand K; Lock K; MacDonald S; Guh D; Schechter MT
    Subst Abuse Treat Prev Policy; 2015 Jan; 10():3. PubMed ID: 25619263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety profile of injectable hydromorphone and diacetylmorphine for long-term severe opioid use disorder.
    Oviedo-Joekes E; Brissette S; MacDonald S; Guh D; Marchand K; Jutha S; Harrison S; Janmohamed A; Zhang DZ; Anis AH; Krausz M; Marsh DC; Schechter MT
    Drug Alcohol Depend; 2017 Jul; 176():55-62. PubMed ID: 28521199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Client satisfaction among participants in a randomized trial comparing oral methadone and injectable diacetylmorphine for long-term opioid-dependency.
    Marchand KI; Oviedo-Joekes E; Guh D; Brissette S; Marsh DC; Schechter MT
    BMC Health Serv Res; 2011 Jul; 11():174. PubMed ID: 21791093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of non-use of illicit heroin in opioid injection maintenance treatment of long-term heroin dependence.
    Oviedo-Joekes E; Sordo L; Guh D; Marsh DC; Lock K; Brissette S; Anis AH; Schechter MT
    Addict Behav; 2015 Feb; 41():81-6. PubMed ID: 25452049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment with injectable hydromorphone: Comparing retention in double blind and open label treatment periods.
    Oviedo-Joekes E; Palis H; Guh D; Marchand K; Brissette S; Harrison S; MacDonald S; Lock K; Anis AH; Marsh DC; Schechter MT
    J Subst Abuse Treat; 2019 Jun; 101():50-54. PubMed ID: 31174713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Double-blind injectable hydromorphone versus diacetylmorphine for the treatment of opioid dependence: a pilot study.
    Oviedo-Joekes E; Guh D; Brissette S; Marsh DC; Nosyk B; Krausz M; Anis A; Schechter MT
    J Subst Abuse Treat; 2010 Jun; 38(4):408-11. PubMed ID: 20359843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Longitudinal patterns of cocaine use among patients receiving injectable hydromorphone or diacetylmorphine for the treatment of opioid use disorder: A growth curve modeling approach.
    Palis H; Guh D; MacDonald S; Harrison S; Brissette S; Marsh DC; Schechter MT; Oviedo-Joekes E
    Drug Alcohol Depend; 2021 Jan; 218():108333. PubMed ID: 33268225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug use, health and social outcomes of hard-to-treat heroin addicts receiving supervised injectable opiate treatment: secondary outcomes from the Randomized Injectable Opioid Treatment Trial (RIOTT).
    Metrebian N; Groshkova T; Hellier J; Charles V; Martin A; Forzisi L; Lintzeris N; Zador D; Williams H; Carnwath T; Mayet S; Strang J
    Addiction; 2015 Mar; 110(3):479-90. PubMed ID: 25251885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Employment and paid work among participants in a randomized controlled trial comparing diacetylmorphine and hydromorphone.
    Nikoo M; Vogel M; Choi F; Song MJ; Burghardt J; Zafari Z; Tabi K; Frank A; Barbic S; Schütz C; Jang K; Krausz M
    Int J Drug Policy; 2018 Jul; 57():18-24. PubMed ID: 29655955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diacetylmorphine versus methadone for the treatment of opioid addiction.
    Oviedo-Joekes E; Brissette S; Marsh DC; Lauzon P; Guh D; Anis A; Schechter MT
    N Engl J Med; 2009 Aug; 361(8):777-86. PubMed ID: 19692689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potency ratio of hydromorphone and diacetylmorphine in substitution treatment for long-term opioid dependency.
    Oviedo-Joekes E; Marsh DC; Guh D; Brissette S; Schechter MT
    J Opioid Manag; 2011; 7(5):371-6. PubMed ID: 22165036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. History of reported sexual or physical abuse among long-term heroin users and their response to substitution treatment.
    Oviedo-Joekes E; Marchand K; Guh D; Marsh DC; Brissette S; Krausz M; Anis A; Schechter MT
    Addict Behav; 2011; 36(1-2):55-60. PubMed ID: 20855171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Injectable opioid agonist treatment for opioid use disorder: a national clinical guideline.
    Fairbairn N; Ross J; Trew M; Meador K; Turnbull J; MacDonald S; Oviedo-Joekes E; Le Foll B; Goyer MÈ; Perreault M; Sutherland C
    CMAJ; 2019 Sep; 191(38):E1049-E1056. PubMed ID: 31548191
    [No Abstract]   [Full Text] [Related]  

  • 18. Differential long-term outcomes for voluntary and involuntary transition from injection to oral opioid maintenance treatment.
    Oviedo-Joekes E; Guh D; Marchand K; Marsh DC; Lock K; Brissette S; Anis AH; Schechter MT
    Subst Abuse Treat Prev Policy; 2014 Jun; 9():23. PubMed ID: 24908387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Injectable opioid agonist treatment: An evolutionary concept analysis.
    Haines M; O'Byrne P
    Res Nurs Health; 2021 Aug; 44(4):664-671. PubMed ID: 33993526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes of Ottawa, Canada's Managed Opioid Program (MOP) where supervised injectable hydromorphone was paired with assisted housing.
    Harris MT; Seliga RK; Fairbairn N; Nolan S; Walley AY; Weinstein ZM; Turnbull J
    Int J Drug Policy; 2021 Dec; 98():103400. PubMed ID: 34469781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.